Tools for Accelerating R&D for Historically Understudied Protein Kinases
Award amount
$1,408,440Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LUCEOME BIOTECHNOLOGIES, L.L.C.
- Proposal award date
- 2017-02-01
- Contract end date
- 2020-01-31
- UEI
- PTPNMPNRP5R1
- Solicitation number
- PAR14-088
- Topic code
- NCATS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Enabling Toxoplasma gondii Kinome Directed Drug Discovery
- Split-luciferase Epigenetic Assays for Drug Discovery
- Kinase Targeted Antimalarial Agents
- Enabling Toxoplasma gondii Kinome Directed Drug Discovery
- Kinome wide Cell Based Assays
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Research funding history
12 SBIR/STTR records share this UEI (2009–2023). Reported award amounts total $9,994,171. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services